FDA expands use of Sapien 3 artificial heart valve for high-risk patients - FDA Press Releases

The U.S. Food and Drug Administration today approved an expanded indication for the Sapien 3 Transcatheter Heart Valve (THV) for patients with symptomatic heart disease due to failure of a previously placed bioprosthetic aortic or mitral valve whose risk of death or severe complications from repeat surgery is high or greater.

from Food and Drug Administration--Press Releases http://ift.tt/2sKLVsS
via IFTTT